• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S Common Stock (NY:NVO)

    44.34 +0.45 (+1.04%)
    Streaming Delayed Price Updated: 1:30 PM EDT, May 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 12,598,593
    Open 44.15
    Bid (Size) 44.33 (300)
    Ask (Size) 44.34 (200)
    Prev. Close 43.88
    Today's Range 43.84 - 44.47
    52wk Range 35.12 - 81.44
    Shares Outstanding N/A
    Dividend Yield 5.75%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Eli Lilly Just Announced Fantastic News for Shareholders ↗
    Lilly's weight loss drugs have been delivering blockbuster revenue. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026) ↗
    The company faces competitive pressure from Novo Nordisk, but it's growing sales from its existing approved drugs and has an exciting drug in its pipeline. 
    Via The Motley Fool

    Performance

    YTD
    -15.4%
    -15.4%
    1 Month
    +19.9%
    +19.9%
    3 Month
    -24.8%
    -24.8%
    6 Month
    -9.7%
    -9.7%
    1 Year
    -36.0%
    -36.0%

    More News

    Read More
    News headline image
    Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent ↗
    Via MarketBeat
    News headline image
    Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge ↗
    Via MarketBeat
    News headline image
    What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. ↗
    Via The Motley Fool
    News headline image
    Is Eli Lilly Stock Undervalued at $870? 1 Top Wall Street Analyst Thinks So ↗
    Via The Motley Fool
    News headline image
    Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means ↗
    Via MarketBeat
    News headline image
    Is This Deal a Game Changer for Novo Nordisk? ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Forget Weight Loss Drugs: Here's An Even Better Reason to Invest in Eli Lilly ↗
    Via The Motley Fool
    News headline image
    This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Street ↗
    Via The Motley Fool
    News headline image
    Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? ↗
    Via The Motley Fool
    News headline image
    Why Eli Lilly Stock Flopped on Friday ↗
    Via The Motley Fool
    News headline image
    Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) ↗
    Via The Motley Fool
    News headline image
    Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap? ↗
    Via The Motley Fool
    News headline image
    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins ↗
    Via The Motley Fool
    News headline image
    Stock Market Today, April 21: Hims & Hers Health Drops as Amazon Unveils Competing Weight Loss Program ↗
    Via The Motley Fool
    Topics Stocks
    News headline image
    A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly ↗
    Via The Motley Fool
    News headline image
    Here's Why Agios Pharmaceuticals Crashed 23% Today ↗
    Via The Motley Fool
    News headline image
    This Drug Stock Has Crushed the S&P 500 Over the Last Decade ↗
    Via The Motley Fool
    Topics Intellectual Property Stocks
    News headline image
    3 Ways to Invest in the Growing GLP-1 Weight Loss Market ↗
    Via MarketBeat
    News headline image
    Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? ↗
    Via The Motley Fool
    News headline image
    Should You Forget CVS Health and Invest in a Purer Healthcare Play? ↗
    Via The Motley Fool
    News headline image
    Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market ↗
    Via The Motley Fool
    News headline image
    The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is Novo Nordisk A/S Common Stock publicly traded?
    Yes, Novo Nordisk A/S Common Stock is publicly traded.
    What exchange does Novo Nordisk A/S Common Stock trade on?
    Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
    What is the ticker symbol for Novo Nordisk A/S Common Stock?
    The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
    What is the current price of Novo Nordisk A/S Common Stock?
    The current price of Novo Nordisk A/S Common Stock is 44.34
    When was Novo Nordisk A/S Common Stock last traded?
    The last trade of Novo Nordisk A/S Common Stock was at 05/04/26 01:30 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.